Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Solid Biosciences (NASDAQ: SLDB) has announced the granting of 43,374 restricted stock units (RSUs) to three newly hired employees. The RSUs are structured with a four-year vesting schedule, with 25% vesting annually on each grant date anniversary. The equity awards, issued under the Company's 2024 Inducement Stock Incentive Plan, are contingent upon continued employment through each vesting date. This compensation package was designed as an inducement for employment and complies with Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – SLDB

-6.89%

1 alert

-6.89% News Effect

On the day this news was published, SLDB declined 6.89%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CHARLESTOWN, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 43,374 restricted stock units (“RSUs”) to three newly hired employees.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

How many restricted stock units (RSUs) did Solid Biosciences (SLDB) grant to new employees in April 2025?

Solid Biosciences granted 43,374 RSUs to three newly hired employees.

What is the vesting schedule for SLDB's April 2025 RSU grants?

The RSUs vest in four equal installments, with 25% vesting on each anniversary of the grant date over four years.

Under which plan were SLDB's April 2025 RSU grants issued?

The RSUs were granted under Solid Biosciences' 2024 Inducement Stock Incentive Plan.

What conditions must be met for the SLDB RSU grants to vest?

Recipients must maintain continued employment with Solid Biosciences through each applicable vesting date.